PreviousEntry : {EA57DCB6-2929-4C79-B352-38105D563266} | Display Title : Container Closure Integrity Testing (CCIT) - What Does It Mean?
NextEntry : {D07EA929-5791-437E-99F2-27CD2C425EF8} | Display Title : Seal Integrity Testing Using the Tracer Gas Method

2.Particulate Matter in Injectable Drug Products, Stephen E. Langille, PDA J. Pharm Sci and Tech 2013 10.5731/pdajpst.2013.00922
3.Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality, John F. Carpenter et all Published online 14 Aug 2008 in Wiley InterScience DOI 10.1002/jps.21530
4. Aggregation and Particle Formation of Therapeutic Proteins in Contact with a Novel Fluoropolymer Surface Versus Siliconized Surfaces: Effects of Agitation in Vials and in Prefilled Syringes, Brandon M. Teska, Jeffery M. Brake, Gregory S Tronto, John F. Carpenter, J. Pharm Sci, 13 Apr 2016
5.Particles in Therapeutic Protein Formulations Part 1: Overview of Analytical Methods, Sara Zolls et all, Published online 08 Dec 2001 in Wiley Online Library DOI 10.1002/jps.23001
6.Industry Perspective on the Control of Visible Particles, Tapan Das, European Biopharmaceutical Enterprises Satellite Session CMC Strategy from Europe 2017, May22-24 Killarney< Ireland
7.Impact of Residual Impurities and Contaminants on Protein Stability, Wei Want, Arun Alphonse Ignatius, Satosh V. Thakkar, Wiley Periodicals, Inc. and the American Pharmacists Association Published by Elsevier 2014

Previous Next
John Rech

John Rech

Manager, Particle Tech, Lab

Subscribe to receive the latest blog post